Randomized, Placebo-controlled, Double-blind, Single-center Trial to Evaluate the Possible Action of Resveratrol in Improving the Outcomes of Controlled Ovarian Stimulation During the IVF/ICSI Cycles in Couples With Unexplained Infertility

Based on available evidence and given the potential beneficial effects of resveratrol in folliculogenesis and in oocyte development, the investigators designed a randomized, controlled, double-blind, single-center trial, whose objective will be the comparison of biological and clinical outcomes of resveratrol supplement in women undergoing IVF/ICSI cycles for unexplained infertility.
To the knowledge of the investigators, no study has been published on the potential effect of resveratrol on IVF/ICSI outcomes considering couples with this infertility diagnosis, which may be the natural target of this integrative treatment because the process of folliculogenesis and oocyte maturation cannot be routinely investigated. An alteration of these biological mechanisms could be the unrecognized cause of part of the unexplained infertility and treatment with resveratrol could result in significant clinical improvement for the patients enrolled in the study.
In more details, the main objective of this randomized, placebo-controlled, double-blind, single-center trial will be the evaluation of the possible effect of resveratrol in determining a better follicle development in patients with unexplained infertility undergoing controlled ovarian stimulation (COS) for IVF/ICSI.
Infertile female patients with normal ovarian reserve will be treated according to clinical practice and the difference between expected (through AFC) and retrieved oocytes will be assessed in relation to use of resveratrol.

开始日期2024-06-01

申办/合作机构-

NCT05994378 / Active, not recruiting临床3期

To Compare the Efficacy and Safety of Oral SHR7280 Tablets With Ganirelix Acetate Injection in Female Subjects With Infertility Receiving Controlled Ovarian Hyperstimulation Therapy: A Multi-center, Randomized, Parallel-Group, Double-Blind, Dual-Simulation, Non-Inferiority Phase III Clinical Study

This study is a multi-center, randomized, double-blind, positive drug-controlled, non-inferiority Phase III clinical trial. The study will enroll approximately 316 infertile female subjects undergoing controlled ovarian hyperstimulation (COH) for in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) treatment.

开始日期2023-08-29

申办/合作机构

江苏恒瑞医药股份有限公司

NCT05751252 / Not yet recruiting早期临床1期IIT

Short-term GnRH- Antagonist Treatment to Lower LH Pulsatility in Women With PCOS Aiming to Improve Hormonal Functions

The clinical study using a sub-therapeutic dose of a GnRH antagonist to reduce overactive LH pulsatility in women with PCOS. With the intervention and lowered LH action we anticipate to decrease androgen levels in women with PCOS. The aim to show for the first time that low-dose GnRH-antagonists can lower LH pulsatility by 20-30% and decrease androgen levels without blunting the hypothalamic-pituitary-gonadal axis and thereby the reproductive functions.

开始日期2023-07-01

申办/合作机构

Centre Hospitalier Universitaire de Lille

100 项与醋酸加尼瑞克相关的临床结果

登录后查看更多信息

100 项与醋酸加尼瑞克相关的转化医学

登录后查看更多信息

100 项与醋酸加尼瑞克相关的专利（医药）

登录后查看更多信息

176

项与醋酸加尼瑞克相关的文献（医药）

2024-08-01·JOURNAL OF PHARMACEUTICAL SCIENCES

Drug-Leachable Interaction Product Evaluation in Prefilled Syringe of Ganirelix Acetate Injection

Article

作者: Sharma, Nitish ; Mule, Dinesh ; Shah, Ravi P ; Badgujar, Devendra ; Chaturvedi, Sachin ; Paritala, Sree Teja

The concept of extractables and leachable has introduced a new era for identifying potential impurities in drug products. Pharmaceutical packaging materials encompass a variety of polymers due to their appealing properties for storing the drug product. However, numerous chemical species may leach into the drug product from these polymers, posing significant health hazards in the public domain. Identifying such leachable is crucial for assessing safety and addressing toxicological concerns. Acrylic acids are commonly used materials for adhering needles to the barrel in pre-filled syringes. In this study, we identified acrylic acid leachable impurities in ganirelix drug products available in the market using mass spectrometry as an analytical technique. These impurities leached into the drug product during storage conditions. Characterization of the impurities was carried out through data obtained from HRMS and MS/MS analysis, revealing them as polyacrylic acid-ganirelix adduct impurities. This study offers valuable insights into identifying leachable and susceptible sites, providing a foundation for potential modifications in similar classes of drug products, thereby enhancing their safety and efficacy.

2024-03-01·Journal of assisted reproduction and genetics

LH supplementation in IVF: human nature, politics, and elephants in the room

Article

作者: Quaas, Alexander M ; Castillo, Juan ; Kol, Shahar

Luteinizing hormone (LH) is present throughout the natural follicular phase. However, the debate is still not settled on whether LH is needed during ovarian stimulation in IVF. This commentary looks at the evolution of this debate, mentioning three elephants in the room that were ignored by the Pharma industry, professional organizations, and clinicians alike: 1. The different endocrinology between the long agonist and the antagonist protocols. 2. The fixed dose of the two most widely commercially available antagonist preparations, namely cetrorelix and ganirelix. 3. The fact that most research in this area uses population-based criteria, ignoring endocrine parameters. Individual genetics of the LH receptor gene may also serve to individualize LH needs during stimulation; however, the jury is still out regarding this approach. CONCLUSIONS: Individual endocrine and genetics parameters may shed meaningful light on the question of LH supplemental during ovarian stimulation.

2024-01-01·Jornal Brasileiro de Reproducao Assistida

Two livebirths achieved in cases of hypergonadotropic hypogonadism nonobstructive azoospermia, treated with GnRH agonist and gonadotrophins: a case series and review of the literature

Review

作者: Matheus, Wagner Eduardo ; Almendra, Antonio Alberto Rodrigues ; Rose, Mauro Bibancos de ; Borges, Edson ; Setti, Amanda Souza ; Garolla, Andrea ; Aguiar, Natalia Alvarenga ; Braga, Daniela Paes de Almeida Ferreira ; Sicard, Arhon Bizelli ; Onório, Beatriz de Oliveira ; Foresta, Carlo

Non-obstructive azoospermia (NOA) is the most severe form of male factor infertility. It results form from either primary or secondary testicular failure. Here, we report cases of two patients with NOA due to maturation arrest and increased serum FSH, treated with GnRH agonist and gonadotrophins. The two NOA patients underwent a pharmacological treatment consisting of pituitary desensibilization using a GnRH agonist and testicular stimulation using menotropin. Testicular stimulation started one month after the beginning of GnRH agonist treatment. The female partner underwent controlled ovarian stimulation (COS) followed by intracytoplasmic sperm injection (ICSI). On the third day of the cycle, menotropin daily doses was administered. When at least one follicle ≥14 mm was visualized, pituitary blockage was performed using GnRH antagonist ganirelix. When three or more follicles attained a mean diameter of ≥17 mm, triptorelin acetate was administered to trigger final follicular maturation. Oocyte retrieval was performed 35 hours later. After treatment, male partner blood levels of the FSH, LH, decreased and total testosterone were increased. Spermatozoa was observed after semen collection in both cases. After COS, oocytes were retrieved and ICSI was performed. Embryos were biopsied for preimplantation genetic testing (PGT) and those considered euploidy were transferred resulting in positive implantation, ongoing pregnancy, and livebirth on both cases. In this report we present a successful strategy for hypergonadotropic hypogonadism AOA men, as an alternative approach to the surgical testicular sperm recovery. Nevertheless, prospective randomized trials are needed to confirm our findings.

项与醋酸加尼瑞克相关的新闻（医药）

2024-11-07

·摩熵医药

37款新药IND获批！68个品种过评，涉及山东新时代药业、浙江华海药业……

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 PART 01 周报概述根据摩熵数据统计，10月28日-11月3日期间共有65个创新药/改良型新药临床申请/上市申请获国家药品监督管理局药品审评中心（CDE）承办（按受理号统计，不含补充申请）。其中，国产药品受理号55个，进口药品受理号10个。本周共计37款创新药/改良型新药临床试验申请获得“默示许可”，包括化学药19款，生物药18款，无中药。在全球创新药研发领域，10月29日，默沙东/Moderna 启动 mRNA 癌症疫苗3期临床试验，针对非小细胞肺癌，同日，阿斯利康（AstraZeneca）的 AZD5492在中国获批临床，拟用于治疗复发性或难治性 B 细胞恶性肿瘤。此外，礼来、正大天晴、恒瑞医药等药企取得新进展。 PART 02 国内37款新药IND获批根据摩熵数据统计，10月28日-11月3日期间共有65个创新药/改良型新药临床申请/上市申请获CDE承办（按受理号统计，不含补充申请）。其中，国产药品受理号55个，进口药品受理号10个。本周共计37款创新药/改良型新药临床试验申请获得“默示许可”，包括化学药19款，生物药18款，无中药。本周获批临床创新药/改良型新药（部分）信息速览(不含补充申请) 注：完整数据可识别“文末”二维码下载查看 PART 03 本周全球TOP10创新药研发进展在全球创新药研发领域，10月29日，默沙东/Moderna 启动 mRNA 癌症疫苗3期临床试验，针对非小细胞肺癌，同日，阿斯利康（AstraZeneca）的 AZD5492在中国获批临床，拟用于治疗复发性或难治性 B 细胞恶性肿瘤。此外，礼来、正大天晴、恒瑞医药等药企取得新进展。本周全球 TOP10 创新药研发进展截图来源：摩熵咨询周报 PART 04 68个品种过评，涉及山东新时代等药企根据摩熵数据统计，10月28日-11月3日期间，共有110项仿制药申报上市/申报临床获CDE承办，其中新注册分类上市申请受理号95项（包括化药3类，4类，5.2类），新注册分类临床申请受理号3项（包括化药3类），一致性评价申请12项；共10个品种通过一致性评价（按受理号计13项），本周58个品种视同通过一致性评价（按受理号计77项）。本周有3项生物类似物注册申报动态，分别是石药集团的注射用奥马珠单抗、菲洋生物的地舒单抗注射液和杭州博之锐生物的帕妥珠单抗注射液。本周过评/视同过评品种主要为心血管系统药物，过评/视同过评产品剂型主要为片剂，本周阿戈美拉汀片和磷酸西格列汀片过评/视同过评受理号数量最多有3个，同时阿戈美拉汀片也是本周过评/视同过评企业数最多的品种。截图来源：摩熵咨询周报在企业层面，本周山东新时代药业有限公司、瑞迪博士和宁波美诺华天康药业有限公司等多家企业过评/视同过评品种数高达2种，其余各企业过评/视同过评品种数紧随其后，本周过评/视同过评企业共包括山东新时代药业有限公司、瑞迪博士和宁波美诺华天康药业有限公司等68家企业。截图来源：摩熵咨询周报本周有苯磺酸氨氯地平片、头孢克洛干混悬剂、对乙酰氨基酚缓释片、波生坦片、磷酸可待因片、非那雄胺片6个品种首次过评/视同过评。本周首次过评/视同过评品种截图来源：摩熵咨询周报本周有醋酸加尼瑞克注射液、阿戈美拉汀片、酒石酸溴莫尼定滴眼液等5个品种过评/视同过评达5家企业。截图来源：摩熵咨询周报根据摩熵数据统计，10月28日-11月3日期间，全球医药大健康行业共发生投融资事件70起，较上次数量增加了6起，其中创新药类融资共31起，医疗器械耗材投资热度也较高，本周占比为27%，为19起。截图来源：摩熵咨询周报国内医药大健康行业共发生投融资事件22起，较上周数量增加了7起，其中医疗/医药技术、医疗服务、医疗器械耗材融资事件分别发生1起、2起、8起；其中宁丹新药、执鼎医疗、瑞普晨创、华昊中天、思纳福医疗、思纳福医疗、恒敬生物、华恒生物、鼎植医生集团融资金额在1亿元人民币以上。截图来源：摩熵咨询周报本周国内创新药大类，抗肿瘤药物研发为热点。如需获取更多行业信息，请订阅摩熵咨询周报。摩熵咨询完整周报识别二维码领取下载往期周报回顾 # 49款新药IND获批！超2亿注射剂，江苏药企迎来过评…… # 39款新药IND获批！52个品种过评，涉及科伦石家庄四药…… # 19款新药IND获批！41个品种过评，浙江高跖医药等3家药企…… # 31款新药IND获批！105个品种过评，石四药等2家药企领跑…… END 本文为原创文章，转载请留言获取授权更多详细报告获取方式后台回复关键词“周报1”，获取2月26日-3月3日周报PDF。后台回复关键词“周报2”，获取3月4日-3月10日周报PDF。后台回复关键词“周报3”，获取3月11日-3月17日周报PDF。后台回复关键词“周报4”，获取3月18日-3月24日周报PDF。后台回复关键词“周报5”，获取3月25日-03月31日周报PDF。后台回复关键词“周报6”，获取4月1日-4月7日周报PDF版。后台回复关键词“周报7”，获取4月8日-4月14日周报PDF版。后台回复关键词“周报8”，获取4月15日-4月21日周报PDF版。后台回复关键词“周报9”，获取4月22日-5月5日周报PDF版。后台回复关键词“周报10”，获取5月6日-5月12日周报PDF版。后台回复关键词“周报11”，获取5月13日-5月19日周报PDF版。后台回复关键词“周报12”，获取5月20日-5月26日周报PDF版。后台回复关键词“周报13”，获取5月27日-6月2日周报PDF版。后台回复关键词“周报14”，获取6月3日-6月9日周报PDF版。后台回复关键词“周报15”，获取6月10日-6月16日周报PDF版。后台回复关键词“周报16”，获取6月17日-6月23日周报PDF版。联系我们，体验摩熵医药更多专业服务会议合作园区服务数据库咨询定制服务媒体合作点击阅读原文，了解更多品牌升级详情！

临床申请疫苗信使RNA临床2期临床1期

2024-11-01

·摩熵医药

2亿注射剂大品种，扬子江拿下！

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 10月29日，据NMPA官网最新公示，扬子江药业集团江苏紫龙药业以仿制4类报产的醋酸加尼瑞克注射液获批并通过一致性评价。据摩熵医药数据库显示，该品种在2023年全国院内市场的销售额逼近2亿元。截图来源：NMPA 醋酸加尼瑞克原研厂家为欧加农（从默沙东分拆而来）。是辅助生殖领域的降调药。作为促性腺激素释放激素(GnRH)拮抗剂，专为在接受辅助生殖技术(ART)控制性卵巢刺激(COS)方案的妇女中使用，用于预防过早出现促黄体激素(LH)峰。在原研和正大天晴共同推动下，国内院内市场销售快速增长。据摩熵医药数据库显示，该品种在2023年全国院内市场的销售额逼近2亿元，同比增长达9.50%。截图来源：摩熵医药（原药融云）全国医院销售数据库除原研（欧加农），国内市场还有正大天晴、南京康舟医药、深圳翰宇药业、齐鲁制药4家药企的醋酸加尼瑞克注射液已获批上市，扬子江药业集团江苏紫龙药业为该产品国产第5家。截图来源：摩熵医药（原药融云）中国药品批文数据库目前，在仿制药布局方面醋酸加尼瑞克注射液有辰欣药业、湖南科伦制药等6家药企提交了4类仿制申请，均在审评审批中。截图来源：摩熵医药（原药融云）中国药品审评数据库 2024年至今，扬子江药业集团江苏紫龙药业有吸入用乙酰半胱氨酸溶液、磷酸特地唑胺片、醋酸加尼瑞克注射液3个品种获批并过评。 END 本文为原创文章，转载请留言获取授权近期热门资源获取后台回复关键词“深度报告”，获取价值18600元，报告大礼包后台回复关键词“2023首仿”，获取2023年首仿药物获批名单后台回复“GLP-1深度报告”，获取完整《GLP-1产业现状与未来发展》PDF版。后台回复“中国 I 类新药”，获取完整《中国 I 类新药靶点》PDF版。后台回复“NAFLD/NASH”，获取完整《NAFLD/NASH报告》PDF版。后台回复“AI+制药”，获取完整《中国AI制药企业白皮书》PDF版。后台回复“XXG”，获取完整《中国心血管系统药物分析报告》PDF版。后台回复“FZZJ”，获取完整《基于剂型改良的复杂注射剂分析》PDF版。后台回复“药品进出口”，获取完整《中国药品进出口白皮书》深度报告-PDF版。联系我们，体验摩熵医药更多专业服务会议合作园区服务数据库咨询定制服务媒体合作点击阅读原文，了解更多品牌升级详情！

一致性评价医药出海上市批准

2024-10-11

·立国制药

行业动态丨203个药品备战第十批国家集采！

进入十月，第十批集采如箭在弦，目前未纳入国采且满足5家及以上竞争条件的有203个品种，涵盖13个治疗大类，集中在消化系统及代谢药、心脑血管系统药物、神经系统药物、全身用抗感染药物和血液和造血系统药物领域。这203个备战第十批集采的品种2023年在中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院(简称中国公立医疗机构)终端的销售规模合计超过1400亿元。从品种来看，共有40余个为超10亿大品种，包括间苯三酚、亚胺培南西司他丁、达肝素、氨苄西林、法莫替丁等注射剂；此外还有依帕司他、西格列汀、沙库巴曲缬沙坦、利格列汀等10余个口服常释剂型等。从企业情况来看，业内预计，在本轮集采中，齐鲁制药、倍特药业、科伦药业、扬子江药业、石家庄四药、复星医药、石药集团、华润医药等头部仍为“主力军”，包括齐鲁制药、倍特药业、科伦药业、扬子江药业、石家庄四药、复星医药、石药集团涉及品种数均达30个以上。其中，齐鲁制药乃是往届的集采“大赢家”，在第九批国家药品集采中，公司旗下共有6款产品拟中选，其中5个产品为近一年来新上市，覆盖抗肿瘤、抗感染等类别。在前9轮国家药品集采中，该公司累计中标64个品种。迎战第十批集采，齐鲁制药共有46个品种冲刺在即，数量依旧靠前。值得一提的是，其备战第十批集采的品种当中，盐酸特比萘芬喷雾剂、ω-3脂肪酸乙酯90软胶囊、达肝素钠注射液、达格列净片、达沙替尼片、瑞戈非尼片、醋酸加尼瑞克注射液、富马酸伏诺拉生片、马来酸阿伐曲泊帕片、马昔腾坦片、二甲双胍恩格列净片、磷酸特地唑胺片、盐酸多柔比星脂质体注射液、注射用醋酸西曲瑞克、米拉贝隆缓释片、艾曲泊帕乙醇胺片等为2024年新获批品种。科伦药业、倍特药业均以37个品种紧跟其后，具体来看，科伦药业包括21个注射剂、14个口服常释剂型等，其中瑞戈非尼片、艾地骨化醇软胶囊、麦考酚钠肠溶片、己酮可可碱注射液、间苯三酚注射液、奥拉帕利片、艾曲泊帕乙醇胺片等均为2024年新获批品种。倍特药业则涉及17个注射剂、11个口服常释剂型、8个口服液体剂、1个吸入剂等，其中盐酸丙卡特罗口服溶液、倍他米松磷酸钠注射液、尼莫地平口服溶液、重酒石酸去甲肾上腺素注射液、瑞巴派特片、马来酸阿伐曲泊帕片、左西孟旦注射液、西洛他唑片、马来酸氟伏沙明片、依帕司他片、重酒石酸间羟胺注射液、钆特酸葡胺注射液、达格列净片等为2024年新获批品种。上述药企的2024年新获批品种若成功通过集采谈判，意味着这些品种有望实现快速放量。

带量采购上市批准

100 项与醋酸加尼瑞克相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04302	醋酸加尼瑞克	H01CC01	DB06785

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
女性不孕症	日本	Organon KK	2008-07-16
卵巢过度刺激综合征	欧盟	Organon NV	2000-05-16
卵巢过度刺激综合征	冰岛	Organon NV	2000-05-16
卵巢过度刺激综合征	列支敦士登	Organon NV	2000-05-16
卵巢过度刺激综合征	挪威	Organon NV	2000-05-16
早产	美国	Organon USA LLC	1999-07-29

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01614067 (DOS/DOR, CTgov)	临床4期	不孕 \| 卵巢储备减少	30	Ganirelix acetate (Delayed Start)	糧顧膚獵壓齋鹽積鏇簾(選淵齋淵積鏇齋餘選廠) = 獵糧廠鑰蓋糧蓋網選鹽網築襯遞選蓋窪窪襯獵 (壓鬱築鹹壓積憲遞繭憲, 糧遞窪蓋廠構願網醖願 ~ 窪鬱築範範鑰選觸網願) 更多	-	2021-06-15
				Ganirelix acetate (Conventional Start)	糧顧膚獵壓齋鹽積鏇簾(選淵齋淵積鏇齋餘選廠) = 範窪醖齋衊製糧醖衊廠網築襯遞選蓋窪窪襯獵 (壓鬱築鹹壓積憲遞繭憲, 衊製憲構鬱鏇窪築廠繭 ~ 遞網糧簾夢鹽艱鏇鹹窪) 更多
NCT00608062 (SHAPE, CTgov)	N/A	雌激素缺乏症状 \| 动脉粥样硬化	155	GnRHant - Ganirelix acetate+Transdermal estradiol patch (Pre1)	鑰窪鹹夢齋衊艱壓艱獵(製顧蓋淵糧鬱夢衊鑰顧) = 夢鏇鹽簾餘製憲鹹繭鹹構鬱壓顧醖壓築願淵廠 (糧鏇壓餘選獵鑰鏇鹽夢, 餘獵顧製憲願鑰醖觸鏇 ~ 膚餘積選壓鬱遞艱廠遞) 更多	-	2020-12-24
				Transdermal placebo patch+GnRHant - Ganirelix acetate (Pre2)	鑰窪鹹夢齋衊艱壓艱獵(製顧蓋淵糧鬱夢衊鑰顧) = 積醖醖襯鏇憲築鏇夢鬱構鬱壓顧醖壓築願淵廠 (糧鏇壓餘選獵鑰鏇鹽夢, 觸廠餘繭夢廠膚築網範 ~ 糧鹽淵憲醖鹽範衊繭蓋) 更多
NCT00802360 (CTgov)	临床4期	不孕	173	Ganirelix+Menotropin+Progestrone vaginal insert (Menopur/Endometrin)	築範齋簾願餘選鬱壓醖(觸鑰願膚範簾醖蓋鹽糧) = 觸餘築蓋衊簾製鬱鹹鬱蓋膚製簾簾糧淵願齋鬱 (鹹艱壓蓋襯衊獵衊繭憲, 顧窪壓夢遞製襯窪蓋繭 ~ 鹽醖襯遞糧鹹簾醖繭顧) 更多	-	2011-08-30
				Ganirelix+Menotropin+Progesterone in oil (Menopur/Progesterone in Oil)	築範齋簾願餘選鬱壓醖(觸鑰願膚範簾醖蓋鹽糧) = 糧鹽淵鹹齋繭鹹積齋鬱蓋膚製簾簾糧淵願齋鬱 (鹹艱壓蓋襯衊獵衊繭憲, 觸鑰醖鹽窪願淵鹽壓範 ~ 鏇鏇願簾夢鏇願壓壓簾) 更多
NCT00724789 (Pubmed \| Hum Reprod)	N/A	卵巢刺激	1,000	Ganirelix	製淵齋顧壓鹽遞築淵顧(壓憲遞鏇網淵憲窪選選) = 製膚簾獵製獵糧觸襯膚鑰壓鹽廠糧製願窪顧壓 (鬱鏇鑰鹽繭遞構觸製齋 )	-	2010-06-01
				GnRH agonist (buserelin)	製淵齋顧壓鹽遞築淵顧(壓憲遞鏇網淵憲窪選選) = 衊選窪齋獵憲鬱簾繭簾鑰壓鹽廠糧製願窪顧壓 (鬱鏇鑰鹽繭遞構觸製齋 )
1007 (AUA2010)	N/A	膀胱过度活动症	14	Ganirelix	網鹽齋窪觸觸構製觸淵(憲鏇艱製醖襯網淵範齋) = 範鬱選艱構繭網顧糧築窪遞鹹鬱遞窪艱範顧遞 (壓夢積醖遞構獵網簾構 ) 更多	-	2010-04-01
				Saline vehicle	網鹽齋窪觸觸構製觸淵(憲鏇艱製醖襯網淵範齋) = 鏇鏇顧衊蓋憲蓋夢鏇餘窪遞鹹鬱遞窪艱範顧遞 (壓夢積醖遞構獵網簾構 ) 更多
NCT00725491 (P05703 \| 38651, CTgov)	临床3期	卵巢过度刺激综合征	259	human chorionic gonadotropin (hCG) (Ganirelix)	選糧夢簾醖夢夢糧衊鏇(願願鹽襯憲淵鹹獵窪觸) = 衊鹽醖鏇齋繭衊鬱衊構餘願簾願醖遞壓衊蓋淵 (構襯製獵夢範繭構衊夢, 願餘範襯糧淵鏇壓窪網 ~ 構壓顧壓願鬱艱餘顧遞) 更多	-	2010-01-22
				Triptorelin (Triptorelin)	選糧夢簾醖夢夢糧衊鏇(願願鹽襯憲淵鹹獵窪觸) = 廠糧艱網齋簾夢糧窪構餘願簾願醖遞壓衊蓋淵 (構襯製獵夢範繭構衊夢, 壓製觸網繭鹽簾淵願製 ~ 網衊製鏇醖襯積鏇製餘) 更多